5072-26-4
中文名稱
丁基硫
英文名稱
DL-BUTHIONINE-[S,R]-SULFOXIMINE
CAS
5072-26-4
EINECS 編號(hào)
246-685-1
分子式
C8H18N2O3S
MDL 編號(hào)
MFCD00070309
分子量
222.31
MOL 文件
5072-26-4.mol
更新日期
2023/03/20 17:41:19
5072-26-4 結(jié)構(gòu)式
基本信息
中文別名
丁基硫丁硫胺酸亞砜胺(BSO)
DL-丁硫氨酸(S,R)-亞砜亞胺
英文別名
DL-BUTHIONINE (R,S)-SULFOXIMINEDL-BUTHIONINE-[S,R]-SULFOXIMINE
DL-BUTHIONINE (S,R)-SULPHOXIME
DL-BUTHIONINE-SULFOXIMINE
2-amino-4-(s-butylsulfonimidoyl)-butanoicaci
2-amino-4-(s-butylsulfonimidoyl)butanoicacid
buthioninesulfoxamine
buthioninesulfoximine
buthioninesulphoximine
butioninesulfoximine
s-(3-amino-3-carboxypropyl)-s-butyl-sulfoximin
Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-.
NSC 381100
S-(3-Amino-3-carboxypropyl)-S-butylsulfoximine
2-Amino-4-(S-butylsulfonimidoyl)butyric acid
所屬類別
原料藥：抗腫瘤藥物理化學(xué)性質(zhì)
熔點(diǎn)215 °C (dec.)(lit.)
沸點(diǎn)382.3±52.0 °C(Predicted)
密度1.29±0.1 g/cm3(Predicted)
儲(chǔ)存條件2-8°C
溶解度H2O: 50 mg/mL, clear, colorless
形態(tài)蓬松粉末
顏色白色
Merck13,1520
BRN2367136
CAS 數(shù)據(jù)庫(kù)5072-26-4(CAS DataBase Reference)
安全數(shù)據(jù)
警示詞警告
危險(xiǎn)性描述H315-H319-H335
危險(xiǎn)品標(biāo)志Xi
危險(xiǎn)類別碼R36/37/38
安全說(shuō)明S26-S36
WGK Germany3
RTECS號(hào)EK7713435
F10
海關(guān)編碼29309090
丁基硫價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | 30947 | DL-丁硫氨酸(S,R)-亞砜亞胺 DL-Buthionine (S,R)-sulfoximine, 99%, Thermo Scientific Chemicals | 5072-26-4 | 500mg | 2107元 |
| 2024/11/08 | 30947 | DL-丁硫氨酸(S,R)-亞砜亞胺 DL-Buthionine (S,R)-sulfoximine, 99%, Thermo Scientific Chemicals | 5072-26-4 | 5g | 18543元 |
| 2024/11/08 | HY-106376 | 丁基硫 DL-Buthionine-(S,R)-sulfoximine | 5072-26-4 | 50mg | 600元 |
常見(jiàn)問(wèn)題列表
生物活性
DL-Buthionine-Sulfoximine (BSO, DL-Buthionine-(S,R)-sulfoximine)是一種 glutathione (GSH) 合成的抑制劑。靶點(diǎn)
| Target | Value |
|
GSH
() |
體外研究
Buthionine sulfoximine is an analogs of methionine sulfoximine and inhibits gamma-glutamylcysteine synthetase about 20 times more effectively than prothionine sulfoximine and at least 100 times more effectively than methionine sulfoximine.
體內(nèi)研究
Treatment of mice bearing HT1080 and HT1080/DR4 xenografts with a continuous i.v infusion of nontoxic doses of D,L-Buthionine-(S,R)-sulfoximine (300 and 600 mg/kg/day) produce a 60% reduction of GSH plasma levels and greater than 95 % reduction in GSH tumor levels in both parental and multidrug-resistant tumors.